ImageneBio Inc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $48.4M
- Price
- $4.26
- % Change (Daily % change from the live per-ticker quote feed.)
- -7.59%
- Volume
- 30.1K
About
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
Quick stats
Shares outstanding11.4M
Computed float11.0M
Float / shares96.5%
Cash runway (months)28.8
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001835579
Websitehttps://imagenebio.com
AI Summary
AI-generated1/10
minorneutralother
ImageneBio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ImageneBio granted inducement awards of 90,775 RSUs and 32,725 non-qualified stock options to three newly hired non-executive employees on September 30, 2026.
The awards were made under the company's 2025 Equity Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4), with RSUs vesting over four years and NSOs exercisable at $4.58 per share, the September 30 closing price.
This is routine equity compensation boilerplate with no bearing on the company's clinical pipeline, including the ongoing Phase 2b trial of olevaprubart in atopic dermatitis.